Page 4 - Johnson & Johnson

One year on

Ravages of last year's lockdown may still affect economy

Vaccinating India: What next?

We must pull out all the stops to win the race against the virus. And trust each other to do the right thing

Clot mystery thickens: Opinion divided over AstraZeneca vaccine roll-out

Thailand, Bulgaria delay jab launch; WHO, France, Germany support shot

WHO grants emergency authorization for J&J Covid-19 vaccine

The World Health Organization granted an emergency use listing Friday for the coronavirus vaccine made by Johnson & Johnson, meaning the one-dose shot can now theoretically be used as part of the international COVAX effort to distribute vaccines globally, including to poor countries without any supplies. In a statement, the U.N. health agency said the ample data from large clinical trials shows the J&J vaccine is effective in adult populations. The emergency use listing comes a day after the European Medicines Agency recommended the shot be given the green light across the 27-country European Union. As new vaccines become available, we must ensure they become part of the global solution and not another reason some countries and people are left further behind, WHO director-general Tedros Adhanom Ghebreyesus said at a Friday press briefing. WHO has previously signed off on COVID-19 vaccines developed by Pfizer-BioNTech and AstraZeneca. A massive study that spanned three ...

European Union authorises Covid vaccine produced by Johnson & Johnson

The European Union (EU) has authorised the use of a Covid-19 vaccine produced by Johnson & Johnson, only hours after the European Medicines Agency (EMA) made a positive recommendation based on scientific assessment of its efficacy and safety.

US to buy additional 100 million doses of J&J's Covid-19 vaccine

President Joe Biden is announcing Wednesday the US is buying an additional 100 million doses of the single-shot Johnson & Johnson coronavirus vaccine. The drugmaker is already obligated to supply 100 million doses to the federal government by the end of June. The additional vaccine would be delivered in the months following. A White House official previewed the news on the condition of anonymity before the president's remarks. The US is set to receive enough doses of the three approved vaccines by the middle of May to cover all adults. The surplus would ensure supply to cover young adults and children, pending the result of safety and efficacy trials. They could also be used as potential boosters to further protect against emerging virus variants, or be shared with allies overseas once Americans are protected.

World Coronavirus Dispatch: Experts question WHO probe into virus origins

Johnson's single-dose can be game changer, Nasdaq wipes out 2021 gains after dovish Powell comments, Calls grow to prioritise Italy's priests for jabs and other pandemic-related news across the globe

Decoded: How Covid-19 vaccine efficacy helps to get an idea of protection

Efficacy of a vaccine means its ability to stimulate immunity in a person who has received the shot

American drugmaker Merck to help produce J&J's Covid-19 vaccine: Biden

US President Joe Biden on Tuesday announced a collaboration between Johnson & Johnson, Merck, and the federal government to ramp up COVID-19 vaccine production.This comes days after the Food and Drugs Administration (FDA) announced that it had approved the Janssen COVID-19 Vaccine for emergency use in the US in individuals 18 years of age and older.Delivering his remarks at the White House, Biden announced the partnership: "Two of the largest health care and pharmaceutical companies in the world that are usually competitors are working together on the vaccine.""This type of collaborations between the countries we have seen in World War II. We have also invoked the defence production act to equip Merck facilities to safely manufacture the J & J vaccine," he addedBiden said that because of a stepped-up production process, the United States will have enough novel coronavirus vaccines for every American adult by the end of May."This country will have enough vaccines supply for ..

Merck to help make Johnson & Johnson's Covid-19 vaccine, says report

President Joe Biden is expected to make the announcement on Tuesday, the report said

J&J Covid vaccine shipping to US, but new deliveries hinge on regulators

(Reuters) - Johnson & Johnson will ship nearly 4 million doses of its newly authorized single-dose COVID-19 vaccine around the United States this week, but a top executive said on Monday that the next round of deliveries is contingent on regulatory approvals at a new plant.

Wall Street set for higher open on J&J vaccine cheer, stimulus optimism

President Joe Biden scored his first legislative win as the House of Representatives passed his $1.9 trillion coronavirus relief package early Saturday

US CDC panel endorses emergency use of Johnson & Johnson Covid-19 vaccine

US' Centers for Disease Control and Prevention (CDC) advisory committee on Sunday has voted to recommend that Johnson & Johnson's COVID-19 vaccine can be given to people ages 18 and older in the United States.The announcement by CDC Director Rochelle Walensky will allow vaccinations to begin as soon as the doses are received, The Hill reported. The Advisory Committee on Immunization Practices voted 12-0, with one recusal, to recommend the use of the Johnson & Johnson vaccine.Walensky called the decision "another milestone toward an end to the pandemic." This comes a day after the Food and Drug Administration (FDA) announced that it had approved Janssen's single-dose COVID-19 Vaccine for emergency use in the US in individuals 18 years of age and older."This vaccine is also another important tool in our toolbox to equitably vaccinate as many people as possible, as quickly as possible," Walensky said in a statement."As a one-dose vaccine, people do not have to return for a ...

J&J's 1-dose shot cleared, giving US 3rd Covid-19 vaccine

The US is getting a third vaccine to prevent COVID-19, as the Food and Drug Administration on Saturday cleared a Johnson & Johnson shot that works with just one dose instead of two. Health experts are anxiously awaiting a one-and-done option to help speed vaccinations, as they race against a virus that already has killed more than 510,000 people in the US and is mutating in increasingly worrisome ways. The FDA said J&J's vaccine offers strong protection against what matters most: serious illness, hospitalizations and death. One dose was 85% protective against the most severe COVID-19 illness, in a massive study that spanned three continents protection that remained strong even in countries such as South Africa, where the variants of most concern are spreading. The more vaccines that have high efficacy that we can get into play, the better, Dr. Anthony Fauci, the top US infectious disease expert, said ahead of the FDA's ruling. Shipments of a few million doses to be divided ...

Johnson & Johnson's Covid-19 vaccine on track for US emergency approval

US regulators are working "rapidly" to finalise emergency use authorisation for a Johnson & Johnson vaccine which is on track to become America's third shot against the coronavirus pandemic which has killed 509,000 people in the last 12 months alone - the country's deadliest year.

FDA advisory panel to review J&J Covid-19 vaccine with thumbs up expected

(Reuters) - A panel of expert advisers to the U.S. Food and Drug Administration began a meeting to discuss Johnson & Johnson's one-dose COVID-19 vaccine on Friday, setting the stage for a possible emergency use authorization as early as this week.

FDA says single-dose shot from J&J vaccine prevents severe Covid-19

Johnson & Johnson's single-dose vaccine offers strong protection against severe COVID-19, according to an analysis released by US regulators that sets the stage for a final decision on a new and easier-to-use shot to help tame the pandemic. The long-anticipated shot could offer the nation a third vaccine option and help speed vaccinations by requiring just one dose instead of two. Food and Drug Administration scientists on Wednesday confirmed that overall the vaccine is about 66% effective at preventing moderate to severe COVID-19, and about 85% effective against the most serious illness. The agency also said J&J's shot is safe. The analysis is just one step in the FDA's evaluation. On Friday, the agency's independent advisers will debate if the evidence is strong enough to recommend the shot. With that advice, the FDA is expected to make a final decision within days. The COVID-19 death toll in the US topped 500,000 this week, and the vaccination drive has been slower than ...

Johnson & Johnson's one-shot Covid-19 vaccine effective, safe: FDA staff

(Reuters) - Johnson & Johnson's one-shot COVID-19 vaccine appeared safe and effective in trials, U.S. Food and Drug Administration (FDA) staff said in documents published on Wednesday, paving the way for its approval for emergency use.

US: Johnson & Johnson says can provide 20 million coronavirus vaccine doses

Drugmaker Johnson & Johnson says it will be able to provide 20 million US doses of its single-shot COVID-19 vaccine by the end of March, assuming it gets the greenlight from federal regulators. J&J disclosed the figure in written testimony ahead of a Congressional hearing on Tuesday looking at the country's vaccine supply. White House officials cautioned last week that initial supplies of J&J's vaccine would be limited. The company reiterated that it will have capacity to provide 100 million vaccine doses to the US by the end of June. That supply will help government officials reach the goal of having enough injections to vaccinate most adult Americans later this year. On a global scale the company aims to produce 1 billion doses this year. US health regulators are still reviewing the safety and effectiveness of the shot and a decision to allow its emergency use is expected later this week. J&J's vaccine would be the first in the US that requires only a single ...

J&J applies to WHO for emergency use listing of Covid-19 vaccine

J&J said an emergency use listing is a prerequisite for supplying vaccines to the COVAX vaccine program, co-led by WHO, which aims to deliver doses to poor and middle-income countries